Guiding Light: Oncology Nurses’ Vital Role in Supporting Patients Through CLL Therapy

Faculty

Amy L. Goodrich, RN, BSN, MSN, CRNP-AC
Moderator
Nurse Practitioner
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Division of Hematologic Malignancies
Baltimore, MD
Nikki Barkett, BSN, RN, OCN
Patient Access Coordinator V
Banner University of Arizona Cancer Center
Matthew S. Davids, MD, MMSc
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Statement of Need

More than 200,000 people in the United States are living with a chronic lymphocytic leukemia (CLL) diagnosis, and it is responsible for approximately 4,410 U.S. deaths each year. The treatment landscape for CLL has changed dramatically in the past 10 years and there are now four FDA-approved Bruton tyrosine kinase inhibitors (BTKis), as well as venetoclax and chemoimmunotherapies, available to clinicians for their patients in the United States, while new, second- and third-generation BTKis and novel combination therapies are emerging. As a result, oncology nurses will be required to navigate varying dosing regimens and adverse event (AE) management approaches with their patients, in order to maximize therapy adherence.

In this Creative Educational Concepts (CEC) webcast, expert faculty will discuss strategies for differentiating patient- and disease-specific variables that inform CLL treatment selection, developing plans for managing new AEs, and addressing patient-related treatment barriers to improve adherence to CLL therapy.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Differentiate patient- and disease-specific variables that inform CLL treatment selection
  • Develop plans for managing AEs arising from new and emerging CLL treatment approaches, as well as long-term and late effects of treatments
  • Incorporate strategies to address patient-related treatment barriers to improve adherence to CLL therapy

Financial Support

This activity is supported by educational grants from BeiGene USA, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.- both are Johnson & Johnson companies; and Lilly.

Target Audience

Oncology nurse practitioners (NPs) and RNs (academic and community)

Credit Information

Jointly Accredited Provider

In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

American Nurses Credentialing Center

This activity is designated for 1.50 contact hours.

American Nurses Credentialing Center with ILNA

This activity is designated for 1.50 contact hours.

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:

OCN®

  • Oncology Nursing Practice (Scientific
  • Basis/Profession)
  • Symptom Management & Palliative Care
  • Psychosocial Dimensions of Care


AOCNP®/AOCNS®

  • Cancer Treatment
  • Side Effect & Symptom Management
  • Psychosocial Issues
  • Professional Practice


CPHON®

  • Cancer Treatment
  • Side Effect & Symptom Management
  • Psychosocial Issues


BMTCN®

  • Professional Performance


CBCN®

  • Nursing Practice (Symptom
  • Management, EoL Care, Professional)
    Psychosocial & Spiritual

Disclosure Declaration

Ms. Goodrich reports the following financial relationships:

Advisory Board: AbbVie Inc.; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.

Ms. Barkett reports no financial relationships to disclose.

Dr. Davids reports the following financial relationships:

Consultant: AbbVie Inc.; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Meyer Squibb Company; Lilly; Genentech, Inc.; GENMA Pharma; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Nuvalent; Secura Bio, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and TG Therapetics, Inc.

Grants: Ascentage Pharma; MEI Pharma, Inc.; and Novartis Pharmaceuticals Corporation

Other financial or material support: UpToDate – authorship royalties

The following individuals have no financial relationships to disclose:

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Evan Luberger (Planning Committee)
Katherine Lee, PharmD (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sharon Tordoff (Planning Committee)

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Visit the Creative Educational Concepts Privacy Policy page for complete information about our privacy policy and practices.

Questions about this activity?

Call us at 859-260-1717  •  info@ceconcepts.com

MMV-141-042724-90

Call us at 859-260-1717  •  info@ceconcepts.com

Guiding Light: Oncology Nurses’ Vital Role in Supporting Patients Through CLL Therapy
Activity Date: 05/07/2024